Eli Lilly reports early Phase 1 data for investigational FRα‑targeting ADC in platinum‑sensitive ovarian cancer at ESMO 2026

Eli Lilly’s Oct. 24, 2026 press release distributed via PR Newswire says the company presented early Phase 1 clinical data at the European Society for Medical Oncology (ESMO) 2026 meeting for an investigational, next‑generation FRα‑targeting antibody–drug conjugate (ADC) administered in combination as a treatment for platinum‑sensitive ovarian cancer.

The release describes this as the "first clinical data" in platinum‑sensitive ovarian cancer for Lilly’s investigational FRα‑targeting ADC and frames the findings as early‑stage (Phase 1) results; the announcement characterizes the therapy as investigational. The press release is the source for this brief and the claims are reported as stated by Lilly.

Report a correction · Editorial standards · Our source directory

BusinessIndy examines this development and its implications for Indiana businesses and communities using the linked sources.

UNVERIFIED REPORT: BusinessIndy has not independently fact-checked this story. It is based on the linked source or submitted lead and may contain errors or change.